Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Galcanezumab reduces cluster headache attack frequency

Publish date:: May 8, 2019

Key clinical point: Galcanezumab reduces weekly cluster headache attack frequency.

Major finding: Mean weekly attack frequency decreased by 8.7 days in the galcanezumab group.

Study details: An eight-week, double-blind, placebo-controlled trial of 106 patients with episodic cluster headache.

Disclosures: Eli Lilly and Co. sponsored the study, and Dr. Dodick has a consulting relationship with the company.

Citation:

Bardos JN et al. AAN 2019. Abstract 02.004.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Neurology

HIT-6 may help track meaningful change in chronic migraine,

Vascular dementia risk particularly high in type 2 diabetes,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,

Blood biomarkers could help predict when athletes recover from concussions,

Mortality burden of dementia may be greater than estimated,